Jiajia Feng Email

Scientist I . Portola Pharmaceuticals

South San Francisco, CA

Location

j****@portola.com

Primary Email

Current Roles

Employees:
66
Revenue:
$24M
About
We are dedicated to discovering, developing and commercializing therapies that transform patient lives and advance patient care by changing treatment paradigms in thrombosis and other hematologic diseases. The company's two FDA approved medicines are Bevyxxa® (betrixaban), the first and only oral, once-daily Factor Xa inhibitor, and Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban. The company also is advancing cerdulatinib, a Syk/JAK inhibitor for the treatment of hematologic cancers. These compounds come from our own internal research efforts and represent important advances to address significant unmet needs. We are employing novel strategies that may increase the likelihood of clinical, regulatory and commercial success of our potentially lifesaving therapies.
Portola Pharmaceuticals Address
270 East Grand Ave.
South San Francisco, CA
United States
Portola Pharmaceuticals Email

Past Companies

BMSResearch Scientist
Portola PharmaceuticalsScientist
NovartisScientist I

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.